GSE133532
BR-body mutant mRNA half-life profiling.
BR-body mutant strains were globally profiled for mRNA half-lives using rifampicin treatment followed by RNA-seq.  JS38 (wild type) was compared to JS221 (lacking the intrinsically disordered CTD and unable to form BR-bodies), JS233 (unable to recruit degradosome components into BR-bodies), and JS299 (active site mutant of RNase E). Overall design: BR-body mutant strains were globally profiled for mRNA half-lives using rifampicin treatment followed by RNA-seq.  Biological samples were taken before treatment, then at 1, 3, and 9 minutes after rifampicin treatment.